Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
- 24 December 1999
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 286 (5449) , 2528-2531
- https://doi.org/10.1126/science.286.5449.2528
Abstract
The hCHK2 gene encodes the human homolog of the yeast Cds1 and Rad53 G 2 checkpoint kinases, whose activation in response to DNA damage prevents cellular entry into mitosis. Here, it is shown that heterozygous germ line mutations in hCHK2 occur in Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in the TP53 gene. These observations suggest that hCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and they also provide a link between the central role of p53 inactivation in human cancer and the well-defined G 2 checkpoint in yeast.Keywords
This publication has 50 references indexed in Scilit:
- A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphataseCurrent Biology, 1999
- A DNA Damage Checkpoint Meets the Cell Cycle EngineScience, 1997
- Checkpoints Take the Next StepScience, 1996
- Mutations of GTBP in Genetically Unstable CellsScience, 1995
- A kinase from fission yeast responsible for blocking mitosis in S phaseNature, 1995
- Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair.Genes & Development, 1994
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- p53 germline mutations in Li-Fraumeni syndromeThe Lancet, 1991
- p53 Mutations in Human CancersScience, 1991
- Universal control mechanism regulating onset of M-phaseNature, 1990